Synergy Pharmaceuticals to Present at ROTH 24th Annual Growth Conference
07 Março 2012 - 10:53AM
Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU)
(Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal
disorders and diseases, today announced that its President and CEO,
Gary S. Jacob, Ph.D, will present at the ROTH 24th Annual Growth
Stock Conference on Tuesday, March 13, 2012 at 5:00 p.m. PDT at the
Ritz Carlton in Dana Point, CA.
To access live audio broadcast of this presentation, or the
subsequent 90 day archive, log onto
http://www.synergypharma.com/Investor_Relations_Information.html.
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the
development of new drugs to treat gastrointestinal disorders and
diseases. Synergy's proprietary drug candidate plecanatide is a
synthetic analog of the human gastrointestinal hormone uroguanylin,
and functions by activating the guanylate cyclase C (GC-C) receptor
on epithelial cells of the GI tract. Synergy completed a Phase I
study of plecanatide in healthy volunteers and a Phase IIa clinical
trial in patients to treat chronic idiopathic constipation (CIC)
patients. In October 2011, Synergy initiated a Phase II/III
800-patient, 90-day repeated-oral-dose, placebo-controlled clinical
trial of plecanatide in CIC patients. Plecanatide is also being
developed to treat constipation-predominant irritable bowel
syndrome (IBS-C), with the first trial in IBS-C patients planned
for 2012. Synergy's second GC-C agonist SP-333 is presently in
pre-clinical development to treat inflammatory bowel diseases. More
information is available at http://www.synergypharma.com.
CONTACT: Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Synergy Pharmaceuticals - Warrants da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de